Why Achillion Pharmaceuticals Inc. Shares Were Eviscerated

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Achillion Pharmaceuticals  (NASDAQ: ACHN  ) , a developer of therapies targeting the hepatitis-C virus and other infectious diseases, plummeted as much as 60% following disappointing news from the Food and Drug Administration regarding sovaprevir, its lead hepatitis-C compound.

So what: According to an after-the-bell Friday press release, Achillion noted that the FDA had decided to keep its clinical hold on sovaprevir despite meeting all requirements as laid out in the FDA's clinical hold notification three months ago. The clinical hold stems from an early-stage drug-to-drug interaction trial between sovaprevir and atazanavir in which higher than expected ALT liver enzymes were detected in patients. Achillion noted its disappointment in the FDA's decision but also pointed to three additional clinical-stage drugs to which it can turn to in the meantime.

So what: It's not that hard to understand why this clinical hold is so devastating to shareholders. Achillion represents one of the very few non-nucleotide development programs, yet it can't seem to get its most promising candidate off the ground. Meanwhile, Gilead Sciences' (NASDAQ: GILD  ) sofosbuvir and AbbVie's (NYSE: ABBV  ) direct-acting antiviral combo are progressing exceptionally well, with sofosbuvir currently under FDA review and the DAA combo receiving the highly coveted breakthrough designation and currently in phase 3 trials. In other words, even if Achillion gets sovaprevir back, it's still going to make it to market a good two or three years behind these oral and highly effective drugs from Gilead and AbbVie. Achillion's window of opportunity is closing rapidly and shareholders can see that. I would suggest keeping your distance until there's something tangibly positive from this whole situation.

Two biotech names you should be watching instead
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2661158, ~/Articles/ArticleHandler.aspx, 9/29/2016 8:26:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
ACHN $7.93 Down -0.36 -4.34%
Achillion Pharmace… CAPS Rating: ***
ABBV $62.82 Down -1.40 -2.18%
AbbVie CAPS Rating: ****
GILD $77.86 Down -1.11 -1.41%
Gilead Sciences CAPS Rating: *****